Head and Neck - ARC2019
Radiation oncology residents and practitioners, as well as other health professionals involved in the care of head/neck cancer patients, confront an area of oncology that is widely acknowledged as perhaps the most challenging in the field. This relates to the extremely complex anatomy of this body region, the wide variety of histologies encountered, the multiple and evolving staging systems for different head/neck cancer subsites and related treatment algorithms, the complex interplay between surgery, radiation, conventional chemotherapy, targeted therapy and immunotherapy, and the rapid evolution of both the technology involved and the clinical trials and clinical trial structures addressing fundamental questions.
This session will improve learners’ understanding and implementation of the optimal multi-modality treatment strategies for patients with a variety of head/neck cancer types (sites and histologies) and will incorporate specific recommendations regarding radiation treatment dose and techniques. Learners will be reminded of currently open and recently completed national clinical trials relating to this topic. The session will also address significant controversies regarding leading-edge technologies.
The activity is designed to meet the interests of medical oncologists, radiation oncologists, radiation oncology residents, surgeons, nurses, radiation therapists, and radiation dosimetrists.
- Explain the basic treatment pathways that guide management of head/neck cancer cases (oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, major salivary glands) including the roles of surgery, radiation therapy and use of systemic agents
- Identify the 2018 AJCC staging system for HPV-associated oropharynx cancers
- Develop technical competence in planning head/neck IMRT cases
- Explore the use of leading edge head/neck cancer technologies (proton RT, immunotherapy)
Michael Samuels, MD is employed by the University of Miami and receives compensation/remuneration/funding from Alpha Tau Medical.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.